glutamic acid and Melanoma

glutamic acid has been researched along with Melanoma in 49 studies

Research

Studies (49)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (2.04)	18.7374
1990's	1 (2.04)	18.2507
2000's	13 (26.53)	29.6817
2010's	29 (59.18)	24.3611
2020's	5 (10.20)	2.80

Authors

Authors	Studies
Akingbemi, WO; Bachrach, B; Bui, AAT; Carroll, J; Cummings, AL; Dubinett, SM; Elashoff, D; Fares, CM; Garon, EB; Goldman, JW; Grogan, T; Gukasyan, J; Hornstein, N; Li, D; Lisberg, A; Lu, HY; Noor, Z; Ribas, A; Rossetti, M; Sunga, G; Zaretsky, J	1
Balakin, A; Novak, P; Temnik, M	1
Hajdú, T	1
De Giorgi, V; Gori, A; Massi, D; Pazzagli, M; Pinzani, P; Salvianti, F	1
Banyas, E; Benbenishty, A; Blinder, P; David, S; Goldshmit, Y; Mayo, L; Perelroizen, R; Ruban, A; Shalom, M; Yakovchuk, A	1
Bosenberg, M; Talty, R	1
Liu, T; Qian, J; Suo, A; Wang, Y; Xu, W; Zhao, N	1
Dalley, CB; Wolfe, BB; Wroblewska, B; Wroblewski, JT	1
Chen, S; Eddy, K; Filipp, FV; Shah, R; Singh, SJ	1
Perry, RJ; Rabin-Court, A; Rodrigues, MR; Zhang, XM	1
Li, S; Liang, C; Nemecio, D; Quach, C; Song, Y	1
Edmonds, K; Fearfield, L; Gore, M; Larkin, J; Newton-Bishop, J; Sinha, R	1
D'Alonzo, D; Glatz, K	1
Chen, S; Goydos, JS; Haffty, B; Khan, A; Schiff, D; Shin, SS; Sierra, J; Wall, BA; Wangari-Talbot, J; Yu, LJ	1
Botella, L; Callaghan, RC; Cerda-Nicolas, M; Gil-Benso, R; Gonzalez-Darder, J; Lopez-Gines, C; Muñoz-Hidalgo, L; Navarro, L; Quilis, V; San Miguel, T	1
Albanese, C; DiRaddo, JO; Gelb, T; Grajkowska, E; Hathaway, HA; Pshenichkin, S; Rodriguez, OC; Wolfe, BB; Wroblewska, B; Wroblewski, JT; Yasuda, RP	1
Abildgaard, C; Basse, AL; Dahl, C; Guldberg, P; Ma, T	1
Aza-Blanc, P; Osterman, AL; Ratnikov, B; Ronai, ZA; Scott, DA; Smith, JW	1
Benedict, JJ; DeConti, R; Gibney, GT; Gonzalez, RJ; Kudchadkar, RR; McCardle, T; Messina, JL; Sloot, S; Smalley, KS; Sondak, VK; Turner, LM; Weber, JS; Zager, JS	1
Anniciello, AM; Ascierto, PA; Botti, G; Favoino, E; Feldman, SA; Ferrone, CR; Ferrone, S; Flaherty, KT; Giannarelli, D; Nota, S; Palmieri, G; Pepe, S; Sabbatino, F; Scognamiglio, G; Simeone, E; Villani, V; Wang, Y	1
Baguley, BC; D'mello, SA; During, MJ; Finlay, GJ; Green, TN; Joseph, WR; Kalev-Zylinska, ML; Leung, EY	1
Bastian, BC; Bauer, J; Lutzky, J	1
Blower, PE; Durinck, S; Futreal, AP; Ikediobi, ON; Reimers, M; Stratton, MR; Weinstein, JN	1
Dalla Palma, M; Desai, B; Egyhazi, S; Elder, DE; Flaherty, KT; Hansson, J; Herlyn, M; King, AJ; Lioni, M; Nathanson, KL; Smalley, KS; Van Belle, P; Wu, H; Xiao, M	1
Elder, DE; Flaherty, KT; Herlyn, M; Letrero, R; Nathanson, KL; Nguyen, TK; Smalley, KS; Van Belle, P; Villanueva, J; Wang, Y; Xiao, M	1
Chen, S; Goydos, JS; Shin, SS; Wall, BA	1
Chan, JL; Cohen-Solal, KA; Goydos, JS; Le, MN; Merrigan, KT; Nabatian, AS; Rosenberg, SA	1
Mier, JW; Panka, DJ; Sullivan, RJ	1
Davies, MA; Davis, S; Gartner, J; Gershenwald, JE; Lin, JC; Prickett, TD; Robinson, S; Robinson, W; Rosenberg, SA; Samuels, Y; Stemke-Hale, K; Teer, JK; Walia, V; Wei, X	1
Coral, S; Fratta, E; Maio, M; Parisi, G; Sigalotti, L	1
Barretina, J; Barrett, FG; Birsoy, K; Brachtel, EF; Chan, AM; Chen, WW; Cowley, GS; Driggers, EM; Garraway, LA; Hsu, PP; Jang, HG; Jha, AK; Kalaany, NY; Kim, D; Marks, KM; Mino-Kenudson, M; Ottina, K; Pacold, ME; Possemato, R; Root, DE; Sabatini, DM; Sethumadhavan, S; Shaul, YD; Stransky, N; Tsun, ZY; Woo, HK; Yuan, B	1
Chi, Z; Cui, C; Flaherty, KT; Guo, J; Kong, Y; Li, S; Mao, L; Sheng, X; Si, L; Xu, X	1
Chan, JL; Chen, S; Goydos, JS; Lee, HJ; Namkoong, J; Rosenberg, S; Shin, SS; Wall, BA; Wangari-Talbot, J	1
Chen, S; Teh, JL	1
Ajouaou, A; Dankort, D; Horlings, HM; Kortman, PC; McMahon, M; Meissl, K; Michaloglou, C; Mooi, WJ; Peeper, DS; Possik, PA; Smit, MA; Vredeveld, LC	1
Brunet, JP; Fisher, DE; Golub, TR; Jalili, A; Lupien, M; Mertz, KD; Pashenkov, M; Pathria, G; Ramaswamy, S; Stingl, G; Wagner, C; Wagner, SN; Widlund, HR	1
Abushahba, W; Boregowda, RK; Cohen-Solal, KA; Goydos, JS; Jeong, BS; Lasfar, A; Liu, F; Olabisi, OO; Wen, Y	1
Gao, H; Gao, L; Gao, W; He, CD; Li, L; Liu, J; Liu, Y; Lu, P; Shan, L; Song, Z; Sun, C; Xu, Y; Zhang, Y; Zou, W	1
Barany, F; Elenitsas, R; Seykora, J; Turner, DJ; Zirvi, MA	1
Abbe, P; Bahadoran, P; Bailet, O; Ballotti, R; Baron, V; Bertolotto, C; Gaggioli, C; Ortonne, JP; Robert, G; Spadafora, A; Tartare-Deckert, S	1
Angel, C; Dobrovic, A; Dowling, JP; Kelly, JW; Liu, W; Magee, J; Mason, G; McArthur, GA; Murray, WK; Trivett, M; Wolfe, R	1
Chen, S; Goydos, JS; Lee, HJ; Marín, YE; Namkoong, J; Shin, SS; Wall, BA	1
Haas, HS; Heintz, E; Ingolic, E; Pfragner, R; Schauenstein, K; Schraml, E; Siegl, V	1
Cui, Y; Guadagno, TM	1
Cheung, M; Madhunapantula, SV; Robertson, GP; Sharma, A	1
Horrevoets, AJ; Neels, J; Pannekoek, H; Roelofs, Y; van Meijer, M; van Zonneveld, AJ	1
Pham, HT; Ruediger, R; Walter, G	1
Aubry, JP; Beck, A; Bonnefoy, JY; Bussat, MC; Champion, T; Corvaia, N; Goetsch, L; Haeuw, JF; Julien, E; Klinguer-Hamour, C	1
Aikawa, M; Berzins, K; Perlmann, P; Udomsangpetch, R; Wahlgren, M	1

Reviews

2 review(s) available for glutamic acid and Melanoma

Article	Year
The role of ferroptosis in melanoma. Pigment cell & melanoma research, 2022, Volume: 35, Issue:1 Topics: Animals; Cell Dedifferentiation; Drug Resistance, Neoplasm; Ferroptosis; Glutamic Acid; Humans; Immune Checkpoint Inhibitors; Iron; Melanoma; Signal Transduction; Skin Neoplasms	2022
Glutamatergic signaling in cellular transformation. Pigment cell & melanoma research, 2012, Volume: 25, Issue:3 Topics: Animals; Brain; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Glutamic Acid; Humans; Melanocytes; Melanoma; Mice; Mice, Transgenic; Receptors, Metabotropic Glutamate; Signal Transduction; Skin Neoplasms	2012

Other Studies

47 other study(ies) available for glutamic acid and Melanoma

Article	Year
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. Nature cancer, 2020, Volume: 1, Issue:12 Topics: Carcinoma, Non-Small-Cell Lung; Glutamic Acid; HLA-B Antigens; HLA-B44 Antigen; Humans; Immunotherapy; Lung Neoplasms; Melanoma; Mutation	2020
Anticancer research, 2022, Volume: 42, Issue:12 Topics: Aspartic Acid; Glutamic Acid; Humans; Isotopes; Melanoma; Zinc; Zinc Isotopes	2022
[In vitro examination of N-methyl-D-aspartate type glutamate receptors in non-excitable cells]. Magyar onkologia, 2023, Apr-22, Volume: 67, Issue:1 Topics: Calcium; Glutamic Acid; Humans; Melanoma; N-Methylaspartate; Receptors, N-Methyl-D-Aspartate	2023
Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients. Cancer biomarkers : section A of Disease markers, 2019, Volume: 26, Issue:3 Topics: Amino Acid Substitution; Biomarkers, Tumor; Circulating Tumor DNA; DNA Mutational Analysis; Feasibility Studies; Glutamic Acid; Humans; Liquid Biopsy; Melanoma; Mutation; Neoplastic Cells, Circulating; Proto-Oncogene Proteins B-raf; Real-Time Polymerase Chain Reaction; Skin Neoplasms; Valine	2019
Blood glutamate scavengers increase pro-apoptotic signaling and reduce metastatic melanoma growth in-vivo. Scientific reports, 2021, 07-19, Volume: 11, Issue:1 Topics: Animals; Apoptosis; Aspartate Aminotransferase, Cytoplasmic; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Glioblastoma; Glutamic Acid; Humans; Melanoma; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Oxaloacetic Acid; Recombinant Proteins; Signal Transduction; Tumor Microenvironment	2021
Electrospun PBLG/PLA nanofiber membrane for constructing in vitro 3D model of melanoma. Materials science & engineering. C, Materials for biological applications, 2017, Jul-01, Volume: 76 Topics: Glutamic Acid; Humans; Melanoma; Membranes; Nanofibers; Polyesters; Polyglutamic Acid; Tissue Engineering	2017
The Role of Metabotropic Glutamate Receptor 1 Dependent Signaling in Glioma Viability. The Journal of pharmacology and experimental therapeutics, 2018, Volume: 367, Issue:1 Topics: beta-Arrestins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Glioma; Glutamic Acid; Humans; Melanoma; Proto-Oncogene Mas; Quinolines; Receptors, Metabotropic Glutamate; RNA, Messenger; Signal Transduction	2018
Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1 Cancer research, 2019, 04-15, Volume: 79, Issue:8 Topics: Animals; Apoptosis; Benzeneacetamides; Biological Availability; Cell Proliferation; Drug Therapy, Combination; Female; Glutamic Acid; Glutaminase; Humans; Melanoma; Mice; Mice, Hairless; Neuroprotective Agents; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Thiadiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2019
Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation. PloS one, 2019, Volume: 14, Issue:6 Topics: Alanine; Breast Neoplasms; Cell Line, Tumor; Citrate (si)-Synthase; Colonic Neoplasms; Female; Gene Expression Regulation; Glucose; Glutamic Acid; Humans; Insulin; Isotope Labeling; Ketone Oxidoreductases; Lymphoma, B-Cell; Male; Melanoma; Mitochondria; Obesity; Organ Specificity; Oxidation-Reduction; Phosphorylation; Prostatic Neoplasms; Receptor, Insulin; Signal Transduction; Skin Neoplasms; Small Cell Lung Carcinoma	2019
Revisiting the role of autophagy in melanoma. Autophagy, 2019, Volume: 15, Issue:10 Topics: Amino Acid Substitution; Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Glutamic Acid; Humans; MAP Kinase Signaling System; Melanoma; Proto-Oncogene Proteins B-raf; Signal Transduction; Skin Neoplasms; Valine	2019
Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-01, Volume: 31, Issue:19 Topics: Adult; Antineoplastic Agents; Diagnosis, Differential; Erythema Nodosum; Female; Glutamic Acid; Humans; Indoles; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Panniculitis; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Valine; Vemurafenib	2013
Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib. Mayo Clinic proceedings, 2013, Volume: 88, Issue:12 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Fatal Outcome; Glutamic Acid; Humans; Ileal Neoplasms; Immunohistochemistry; Indoles; Magnetic Resonance Imaging; Male; Melanoma; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Treatment Failure; Valine; Vemurafenib	2013
Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment cell & melanoma research, 2014, Volume: 27, Issue:2 Topics: Acetylcysteine; Apoptosis; Biopsy; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Damage; Gene Knockdown Techniques; Glutamic Acid; Glutathione; Histones; Humans; Intracellular Space; Melanoma; Oxidative Stress; Reactive Oxygen Species; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction	2014
BRAF V600E mutation in two distinct meningeal melanocytomas associated with a nevus of Ota. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jul-10, Volume: 32, Issue:20 Topics: Adolescent; Cell Transformation, Neoplastic; Glutamic Acid; Humans; Male; Melanocytes; Melanoma; Meningeal Neoplasms; Mutation; Nevus of Ota; Proto-Oncogene Proteins B-raf; Signal Transduction; Skin Neoplasms; Valine	2014
Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas. Oncogene, 2015, May-21, Volume: 34, Issue:21 Topics: Animals; Cell Death; Cell Line, Tumor; Cell Survival; Glutamic Acid; Humans; Melanoma; Mice; Mice, Inbred C57BL; Mice, Nude; Quinolines; Receptors, Metabotropic Glutamate	2015
Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition. Journal of translational medicine, 2014, Sep-03, Volume: 12 Topics: Amino Acid Substitution; Cell Proliferation; Dichloroacetic Acid; Drug Resistance, Neoplasm; Drug Synergism; Energy Metabolism; Glutamic Acid; Humans; Indoles; Melanoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Tumor Cells, Cultured; Valine; Vemurafenib	2014
Glutamate and asparagine cataplerosis underlie glutamine addiction in melanoma. Oncotarget, 2015, Apr-10, Volume: 6, Issue:10 Topics: Asparagine; Cell Growth Processes; Glutamic Acid; Glutamine; Humans; Melanoma	2015
BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma research, 2016, Volume: 26, Issue:1 Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Glutamic Acid; Humans; Imidazoles; Indoles; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Mutation, Missense; Neoadjuvant Therapy; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Retrospective Studies; Skin Neoplasms; Sulfonamides; Treatment Outcome; Valine; Vemurafenib	2016
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. Journal of the National Cancer Institute, 2016, Volume: 108, Issue:7 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glutamic Acid; Humans; Immunohistochemistry; Interferon-alpha; MAP Kinase Signaling System; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Proto-Oncogene Proteins B-raf; Receptor, Interferon alpha-beta; Signal Transduction; Skin Neoplasms; Valine	2016
Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate. Cell calcium, 2016, Volume: 60, Issue:6 Topics: Calcium; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Glutamic Acid; Humans; Melanoma; Mutation; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship	2016
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment cell & melanoma research, 2008, Volume: 21, Issue:4 Topics: Aged; Amino Acid Substitution; Anus Neoplasms; Benzamides; Dose-Response Relationship, Drug; Female; Glutamic Acid; Humans; Imatinib Mesylate; Intestinal Mucosa; Lysine; Melanoma; Neoplasm Metastasis; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction	2008
In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Molecular cancer therapeutics, 2008, Volume: 7, Issue:6 Topics: Amino Acid Substitution; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Codon; Drug Screening Assays, Antitumor; Glutamic Acid; Humans; Melanoma; Mutant Proteins; Mutation; Phenothiazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; ras Proteins; Reproducibility of Results; Valine	2008
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Molecular cancer therapeutics, 2008, Volume: 7, Issue:9 Topics: Amino Acid Substitution; Base Sequence; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase 4; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gene Amplification; Glutamic Acid; Humans; Imidazoles; Melanoma; Molecular Sequence Data; Mutation; Proto-Oncogene Proteins B-raf; Valine	2008
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene, 2009, Jan-08, Volume: 28, Issue:1 Topics: Apoptosis; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glutamic Acid; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Valine	2009
AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1). Pigment cell & melanoma research, 2010, Volume: 23, Issue:1 Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Enzyme Activation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamic Acid; Humans; Melanoma; Mice; Mice, Nude; Proto-Oncogene Proteins c-akt; Receptors, Metabotropic Glutamate; Signal Transduction; Skin Neoplasms	2010
The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells. The Journal of investigative dermatology, 2010, Volume: 130, Issue:9 Topics: Cell Division; Cell Line, Tumor; Cell Movement; Excitatory Amino Acid Antagonists; Extracellular Signal-Regulated MAP Kinases; Glutamic Acid; Humans; Melanoma; Naphthalenes; Neoplasm Invasiveness; Organ Culture Techniques; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Skin Neoplasms	2010
An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood. Melanoma research, 2010, Volume: 20, Issue:5 Topics: Amino Acid Substitution; Biopsy; Blood Chemical Analysis; Cell Line, Tumor; Cost-Benefit Analysis; Cytogenetic Analysis; DNA Mutational Analysis; Glutamic Acid; HT29 Cells; Humans; Melanoma; Models, Biological; Proto-Oncogene Proteins B-raf; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Skin Neoplasms; Valine	2010
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nature genetics, 2011, Volume: 43, Issue:5 Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; Base Sequence; DNA Primers; Exons; Genome-Wide Association Study; Glutamic Acid; Humans; Melanoma; Molecular Sequence Data; Mutation; Nuclear Proteins; Oncogenes; Receptors, N-Methyl-D-Aspartate; Sequence Homology, Amino Acid; Signal Transduction	2011
Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success? British journal of cancer, 2011, Jul-12, Volume: 105, Issue:2 Topics: Amino Acid Substitution; Disease Progression; Glutamic Acid; Humans; Melanoma; Mutation, Missense; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins B-raf; Selection, Genetic; Skin Neoplasms; Treatment Outcome; Valine	2011
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature, 2011, Aug-18, Volume: 476, Issue:7360 Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Citric Acid Cycle; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genomics; Glutamic Acid; Humans; Ketoglutaric Acids; Melanoma; Mice; Neoplasm Transplantation; Phosphoglycerate Dehydrogenase; RNA Interference; Serine	2011
Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:1 Topics: Adult; Aged; Amino Acid Substitution; Asian People; Cohort Studies; DNA Mutational Analysis; Female; Genes, ras; Glutamic Acid; Humans; Male; Melanoma; Middle Aged; Mutation Rate; Mutation, Missense; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Valine	2012
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Nov-15, Volume: 17, Issue:22 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glutamic Acid; Indoles; Melanoma; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays	2011
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes & development, 2012, May-15, Volume: 26, Issue:10 Topics: Amino Acid Substitution; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p15; Enzyme Activation; Fibroblasts; Glutamic Acid; Humans; Melanocytes; Melanoma; Nevus; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Skin Neoplasms; Valine	2012
Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. Journal of the National Cancer Institute, 2012, Nov-07, Volume: 104, Issue:21 Topics: Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Blotting, Western; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p18; Cyclin-Dependent Kinase Inhibitor p21; Flow Cytometry; Gene Expression Regulation, Neoplastic; Genes, ras; Glutamic Acid; Glycine; Humans; MAP Kinase Signaling System; Melanocytes; Melanoma; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-jun; RNA, Small Interfering; Transcription Factor AP-1; Transfection; Transplantation, Heterologous; Valine; Viral Vaccines	2012
Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma. PloS one, 2012, Volume: 7, Issue:10 Topics: Animals; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glutamic Acid; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Melanoma; Mice; Phosphorylation; Riluzole; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta; Transplantation, Heterologous; Up-Regulation	2012
Blocking glutamate-mediated signalling inhibits human melanoma growth and migration. Experimental dermatology, 2012, Volume: 21, Issue:12 Topics: Animals; Cell Movement; Cell Proliferation; Chromones; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; HEK293 Cells; Humans; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Microtubules; Neoplasm Invasiveness; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Signal Transduction; Skin Neoplasms; Xenograft Model Antitumor Assays	2012
Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. Journal of cutaneous pathology, 2005, Volume: 32, Issue:5 Topics: Base Sequence; DNA; DNA Mutational Analysis; Dysplastic Nevus Syndrome; Glutamic Acid; Humans; Ligases; Melanocytes; Melanoma; Molecular Sequence Data; Mutation; Nevus; Proto-Oncogene Proteins B-raf; Sensitivity and Specificity; Skin Neoplasms; Valine	2005
Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. The Journal of investigative dermatology, 2007, Volume: 127, Issue:2 Topics: Cells, Cultured; Disease Progression; Early Growth Response Protein 1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fibronectins; Glutamic Acid; Humans; Melanocytes; Melanoma; Mutation; Neoplasm Invasiveness; Proto-Oncogene Proteins B-raf; Signal Transduction; Valine	2007
Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. The Journal of investigative dermatology, 2007, Volume: 127, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Child; Female; Gene Frequency; Glutamic Acid; Humans; Male; Melanoma; Middle Aged; Multivariate Analysis; Mutation; Pigmentation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Threonine; Valine	2007
Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer research, 2007, Mar-01, Volume: 67, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Evaluation, Preclinical; Glutamic Acid; Humans; Melanoma; Mice; Mice, Nude; Mutant Proteins; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Skin Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2007
The non-competitive metabotropic glutamate receptor-1 antagonist CPCCOEt inhibits the in vitro growth of human melanoma. Oncology reports, 2007, Volume: 17, Issue:6 Topics: Antineoplastic Agents; Cell Proliferation; Chromones; Docetaxel; Drug Resistance, Neoplasm; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Melanoma; Receptors, Metabotropic Glutamate; Skin Neoplasms; Taxoids; Tumor Cells, Cultured	2007
B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells. Oncogene, 2008, May-15, Volume: 27, Issue:22 Topics: Amino Acid Substitution; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Genes, cdc; Glutamic Acid; Humans; Melanoma; Phosphorylation; Polymorphism, Single Nucleotide; Protein Binding; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Signal Transduction; Spindle Apparatus; Transfection; Valine	2008
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer research, 2008, May-01, Volume: 68, Issue:9 Topics: Animals; Cell Adhesion; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Chromones; Disease Progression; Glutamic Acid; Humans; MAP Kinase Signaling System; Melanocytes; Melanoma; Mice; Morpholines; Mutant Proteins; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Signal Transduction; Valine	2008
Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator. The Journal of biological chemistry, 1996, Mar-29, Volume: 271, Issue:13 Topics: Alanine; Amino Acid Sequence; Bacteriophages; Base Sequence; Binding Sites; Databases, Factual; DNA, Complementary; Escherichia coli; Gene Library; Glutamic Acid; Humans; Kinetics; Melanoma; Methionine; Molecular Sequence Data; Mutagenesis, Site-Directed; Oligodeoxyribonucleotides; Plasminogen Activator Inhibitor 1; Point Mutation; Restriction Mapping; Thrombin; Tissue Plasminogen Activator	1996
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. Oncogene, 2001, Jan-04, Volume: 20, Issue:1 Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Breast Neoplasms; Female; Glutamic Acid; Glycine; Humans; Lung Neoplasms; Melanoma; Molecular Sequence Data; Neoplasms; Peptide Fragments; Phosphoprotein Phosphatases; Point Mutation; Protein Binding; Protein Phosphatase 2; Protein Structure, Secondary; Tryptophan	2001
Stability and CTL activity of N-terminal glutamic acid containing peptides. The journal of peptide research : official journal of the American Peptide Society, 2001, Volume: 57, Issue:6 Topics: Animals; Anion Exchange Resins; Antigens, Neoplasm; Cancer Vaccines; Cell Line; Chromatography, High Pressure Liquid; Chromium; Epitopes, T-Lymphocyte; Glutamic Acid; Granulocytes; Humans; Immunization; Isoantigens; Melanoma; Mice; Neoplasm Proteins; Peptide Fragments; Peptides; Spectrometry, Mass, Electrospray Ionization; T-Lymphocytes, Cytotoxic	2001
Cytoadherence of knobless Plasmodium falciparum-infected erythrocytes and its inhibition by a human monoclonal antibody. Nature, 1989, Apr-27, Volume: 338, Issue:6218 Topics: Animals; Antibodies, Monoclonal; Antigens, Protozoan; Cell Adhesion; Endothelium, Vascular; Erythrocytes; Fluorescent Antibody Technique; Glutamates; Glutamic Acid; Humans; Melanoma; Microscopy, Electron; Plasmodium falciparum; Repetitive Sequences, Nucleic Acid; Tumor Cells, Cultured	1989